Daniel J. Luckshire: Thanks, Diem. As noted earlier in the call, SIGA's product sales for the 3 months ended June 30, 2025, were $79 million. Product sales for the quarter comprised $53 million of oral TPOXX sales and $26 million of IV TPOXX sales to the U.S. government under the 19C BARDA contract. For the 6 months ended June 30, 2025, product sales are $85 million. In addition to product sales, the company has research and development revenues of approximately $2 million and $3 million for the 3 and 6 months ended June 30, 2025, respectively. As a supplemental note, there are $26 million of remaining outstanding orders as of June 30. This amount reflects the $26 million IV TPOXX order received in the first quarter of this year under the 19C contract, which is targeted for delivery in 2026.